The Bay Area Tumor Institute Community Clinical Oncology Program (BATI-CCOP) is a consortium of 6 community and county hospitals in Greater Oakland, California. It was founded in 1979 as a CGOP and converted to CCOP status in 1989. With a special emphasis on the recruitment of minority, low Income, pediatric, non-English-speaking, and female populations in three Bay Area Counties, the BATI-CCOP enables cancer patients and the general """"""""at risk"""""""" population to participate in the clinical, cancer control and prevention research of CALGB, SWOG, NSABP, RTOG, CTSU, COG, and HLMCC. The long-term objectives and specific aims of the BATI-CCOP include accrual to therapeutic trials at higher rates than comparable CCOPs, accrual of minority and pediatric patients at higher rates than all other CCOPs, aggressive cancer control recruitment that exceeds NCI's cancer control research requirements, and increased interaction with research bases. The CCOP will continue to accrue 95% of all eligible pediatric oncology patients in the region and will continue to excel n the recruitment of minority and female participants, essentially enabling the BATI-CCOP to fulfill the requirements of all three types of CCOP's (an adult CCOP, a Minority-Based CCOP, and a Pediatric CCOP). The CCOP will also continue to exceed NCI mandates and remain the Bay Area leader in accrual to cancer prevention and control trials. The BATI-CCOP offers a successful long-term track record, an organized and committed medical community, experienced physician investigators, institutional and financial support from the Bay Area Tumor Institute, and unusual access to African American, Hispanic, Asian, pediatric, underserved, and female populations.
This research seeks to improve public health by enabling physicians and cancer patients to participate in clinical trials research. The research outcomes are expected to lead to the identification and dissemination of improved methods to diagnose, treat, or prevent cancer.
|Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5|
|Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48|
|Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13|
|Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61|
|Kim, Edward S; Moon, James; Herbst, Roy S et al. (2013) Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol 8:1519-28|
|Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9|
|Smalley, Stephen R; Benedetti, Jacqueline K; Haller, Daniel G et al. (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-33|
Showing the most recent 10 out of 54 publications